GPS_OS_21_vs_SOC_5 Posted - 1 day ago

$SLS Spidey Senses - Partnership / Buyout News While the market often misses major value $SMMT $DRUG $IMGN $CPXX and most* Dumb As F___ Naive Herd Retail don't appreciate the Value of -- 100% Complete Remission Rates for Optimally Dosed ASXL1+, End Stage Dying AML Patients --- Big Pharma Gets It. They Understand the Value.

GPS_OS_21_vs_SOC_5 Posted - 3 days ago

$SLS who remembers $IMGN getting bought for $10B? it was a $270m company 9 months prior, when its p3 data for platinum resistant ovarian cancer results proved a 16.46 month overall survival rate. Gps w Keytruda $MRK achieved a 18.4 month os rate, in the same proc setting... Gps is worth at least this to MRK. — $10B a direct comp for Gps Just For Platinum Resistant Ovarian Cancer.

jdoldnumber7 Posted - 1 week ago

$IMGN va

GPS_OS_21_vs_SOC_5 Posted - 2 weeks ago

@bikechain GPS P3 Data IS Coming. and WE ALL Will Wish We Investing in More down here at just $1.21 - $78M Mcap is going to get bought by Big Pharma for 10B+. $IMGN was at $270M when it Released P3 data, it got bought for $10.1B 6 months later.... Something very similar is about to happen here.

BioSensai Posted - 4 weeks ago

$NVCT and here we are sitting at $150mm with drugs that are both addressing what $imgn and $nuvl had!!!! $imgn = NXP-800 $nuvl = NXP-900

BioSensai Posted - 4 weeks ago

$NVCT Folks this is a $50+ MINIMUM stock after NXP-800 data. Comps are $imgn which sold for $10B after phase 2b and $nuvl which valued at $7b after 1b data

AlexTrades2 Posted - 1 month ago

@patatechaude @osubuck30 hate talking Bo. This stock reminds me of $imgn Bo. once data was positive, huge valuation increase and a quick buyout for a very nice premium. But will they sell? A lot in the pipeline here and got a ways to go.

MisagalCapital Posted - 1 month ago

$IAG $IMGN IAMGOLD is a strong contender in the gold mining sector, recently achieving commercial production at its Côté Gold mine. With robust revenue drivers, positive government relations in Burkina Faso, and a solid technical outlook, it presents a compelling investment opportunity. 📈 Target price: $11! 🏆 #InvestSmart #StockMarketInsights #GOLD #Stockstobuy

Market_Max Posted - 1 month ago

@hope_my_calls_print MM actions. I can’t say for sure what it means but I witnessed a lot of such weeks before $IMGN got acquired in Q4 of 2023. Lots of unusually large trading volumes in regular hours and after hours. So..

GPS_OS_21_vs_SOC_5 Posted - 09/24/24

@BMK00 $IMGN was a $270m mcap when it rleased its p3 data. it was bought for $10B. $cpxx was a $50m mcap when it released its p3 data, it ran to $750m in 3 weeks then it was bought for $1.5B. so just 100% buyout premium, but most of the real money was holding when the p3 data hits.

Namhguab Posted - 09/24/24

@Badrabitt didn’t you short $IMGN too as lost your ass? I mean I see that this one is up since you started shorting it after you finally lost your ass on Imgn you loved to another one and lost your ass on it. Thats the only real trend I’m seeing here.

GPS_OS_21_vs_SOC_5 Posted - 2 months ago

$SLS is better than a Co that recently was bought for $10.1B -- (look at the. $SMMT Chart - same thing is going to happen here. @cea the only way SLS eliminates the entire Commercialization team is because STIFEL told them they have buyouters Lined up. - Recall $IMGN bought for $10.1B $ABBV based on its P3 fda Approval for Elahere 16.46 month OS Results - Gps + Keytruda $MRK achieved an OS of 18.4 months in the same Setting. Yes GPS is better than a 10b Drug. - the many short lowlife were spewing about how IMGN had additional Assets... This was the Second ORR of only 21% / just 5/29 CCr - in R/R AML Cd123+ " At the recommended phase 2 dose, the overall response rate was 21% (95% CI 8–40; six of 29) and the composite complete remission rate was 17% (95% CI 6–36; five of 29)." and 25% grade 3+ TRAE's and 1 Death. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00674-5/abstract

GPS_OS_21_vs_SOC_5 Posted - 2 months ago

@Bionical The Phase 3 ... is why. Once the P3 is IN, it validates the entire GPs Franchise for Mesothelioma, Ovarian Cancer, AML, 20 Cancers express WT1. 1. M. Patients Each Year Are Diagnosed with WT1 Cancer. $IMGN was a 270M co when it released its 16.46 Month P3 Sorraya data for (FRA+) Plat Res Ovarian Cancer - it got bought for 10B not much after... - something similar is going to be happening. here.

quadacesAAAA Posted - 2 months ago

$IMGN $MGNI $IMGN

GPS_OS_21_vs_SOC_5 Posted - 2 months ago

$SLS Gps immunotherapy has been effective in all 9 previous trials w Relapse Prevention and Overall Survival benefits directly correlated with Immune Response. - including a Memorial Sloan Kettering Phase 2 for First Remission (CR1) AML, GPS OS of 67.9 months, w SOC at only 28-35 months. - Second MSKCC CR1 P2 AML was halted early due to Efficacy. Gps 47% OS at 3 years vs only 25% wSCOC - a P2 in Second Remission Cr2 at Moffitt Center w a Statistically Significant OS of 21 months, p value .02, ie 98% reproducibility factor, ie will see same results in 98 of 100 trials. - Gps + Keytruda achieved an os of 18.4 months vs 16 w Elahere that was recently FDA approved for platinum refractory ovarian cancer, $IMGN bought for $10.1B - also Dying Gps+Opdivo Mesothelioma patients achieved an Overall Survival of 27.8 Months vs only 28 Weeks with the current standard of care. $BMY $MRK will be among the big pharma bidding for sls once the p3 results are in. Expect a buyout above $10b.

GPS_OS_21_vs_SOC_5 Posted - 2 months ago

@IBTired -- 1. its worth several billion now and 2. it'll get bought just like $IMGN did...

Night_Owl_Biotech Posted - 2 months ago

We googled "IOVA FY2028 revenue estimates" & got a table by year (attached). For perspective, we took a screenshot of the Centerview Partners written fairness opinion on the Mirati/BMY acquisition where they reviewed 8 M&A transactions, considered peers for Mirati, noting the median year 4 revenue multiple paid was 6.0X. IOVA FY28 revenue estimates = $1.44B so do the math if you believe $IOVA would get a like multiple. Also find a screenshot from Lazard's written fairness opinion on the IMGN/AbbVie transaction. They also reviewed 8 transactions noting the median year 5 multiple paid was 4.0X (mean = 4.2). Notice Lazard notes an $IMGN fair value of up to $20.45/share using year 5 multiples yet IMGN was acquired for $31.45 This is not investment advice. This is for entertainment purposes. We have no idea if IOVA will ever be acquired nor if IOVA would be worth these peer's multiples. Next up will be $DAWN $GERN $SNDX

GPS_OS_21_vs_SOC_5 Posted - 08/29/24

$SLS More Evidence Gps Immunotherapy Works. - earlier I posted GPs + Nivolumab/Opdivo $BMY OS Data for Mesothelioma patients: -- 27.8 Months w GPs vs 28 weeks w SoC. This Graphic shows GPS + Nivo / Opdivo for Ovarian Cancer Trial Results that were stopped early due to Efficacy - again 3X OS advantage, +86% w a Strong, Long Lasting Durable IMMUNE RESPONSE. - OS was directly Correlated with IR, just like the GPS +Keytruda P1/2 Trial for PR/ROC. Gps+Key achieved an OS of 18.4 Months. Elahere $IMGN got FDA approval and bought for $10.1B after achieving 16.46 months. - Keytruda $MRK OS of 13 Months in this Setting as a Monotherapy, w Gps its 18.4 months.

GPS_OS_21_vs_SOC_5 Posted - 08/27/24

$SLS IS A SCREAMING BUY AT THIS PRICE WITH ALL THE ACTION COMING. Gotta give it to the CEO - Cash Runway out to Q3/4 2025, - a Phase 3 Asset about to Unblind Results worth, LITERALLY 100x Plus the current $85M Mcap - a Secondary Asset - SLS009 about to Release Major Max Dose OS Data, a possible STIFEL partnership and FDA Registrational Pathway News for Accelerated Approval, with two Direct Market Comps, each in Phase 2 for AML subsets, each worth Nearly $2B. 009 is worth 25x the whole SLS MCAP. AND -- Shorts are covering, and look at the VOL, no HODLERS are Letting Any Go Before we see the Binary P3 Results - Due 'BY Q4'. Another Fact: GPs + Keytruda $MRK Phase 2 OS Results of 18.4 months for Platinum Relapsed / Refractory Ovarian Cancer Patients, is Better than ELAHERE $IMGN OS 16.46 in the Same Setting - IMGN Just Got Bought for $10.1B. $XBI $BTC.X

kinderspiel Posted - 3 months ago

today $FULC announced the appointment of isabel kalofonos as CCO & heather faulds as chief regulatory affairs & quality assurance officer. together, they will be instrumental in advancing losmapimod towards a new drug application submission & preparing for commercial launch. ms. kalofonos joins fulcrum from $IMGN where she served as senior vice president & chief commercial officer. most recently, ms. faulds served as svp, regulatory affairs at $ALKS

BloodyPortfolio Posted - 3 months ago

$VKTX No Fade for the shorts! It's happening here - $TRIL $IMGN.

GPS_OS_21_vs_SOC_5 Posted - 3 months ago

$SLS $IMGN got bought for $10.1B after its P3 Sorraya trial achieved an Os of 16.46 months for PrOvarian Cancer. Gps +Keytruda $MRK achieved an Os of 18.4 months in the same setting. $75 to $105 Per Share Buyout Price Range once the Phase 3 Results are announced. PRE RDO 103m total shares, all +31.7m RDO shares + warrants, new total 135M - Gps Value in a Buyout $8-$10B $60 to $75 Per Share + $15 to $30 Per Share ($2 to $4B) for 009. - GPS Immunotherapy will treat 25,000 AML Remission Patients each year (+75,000 currently in remission) - CCo published $260K Per patient Minimum Pricing Comps 10,000 AML CR2 Patients (P3 Setting) $2.6B TAM 15-25,000+ in CR1 - Expanded Label $3.5B TAM - Big Pharma's Trade at 4X Price to Sales 4 x $6B $24B Max Value to BP - Just For Gps in AML.

NVDAMillionaire Posted - 3 months ago

$IMGN ImmunoGen, Inc. (NASDAQ:IMGN) – Executing on Commercial Launch and Advancing Robust Pipeline http://beyondspx.com/2024/08/05/immunogen-inc-nasdaqimgn-executing-on-commercial-launch-and-advancing-robust-pipeline/

GPS_OS_21_vs_SOC_5 Posted - 3 months ago

@OnTheBalance @emeraldstocktrader The share price has been manipulated, easily for years, time is up. 80M mcap that has a phase 3 trial result coming due, opening up access to a $6B TAM, that is worth many billions to Big Pharma. I think SLS will get bought for 10B + I said the same thing about $IMGN at $270M it got bought for $10.1B.

GPS_OS_21_vs_SOC_5 Posted - 3 months ago

- forgot to mention, to extend a trial another year, is obviously costly. Updating the clinical.gov site, to meet qc requirements, translates to someone using this data to validate Gps - in some regard. These Gps Nivo $BMY results, are similar to the GPS Keytruda results for Platinum Resistant Refractory Ovarian cancer - a Better Overall Survival rate 18.4 months, than the recently FDA Approved Elehare $IMGN, that got bought for $10.1b.... some Good DD on the GPS Key results in this link. $IMGN was a $270M mcap, pre dilution, when it released its Sorraya P3 trial data. https://www.reddit.com/r/sellaslifesciences/search/?q=Elahere&type=link&cId=b911e43d-bd39-4b80-ba83-9143571eef11&iId=855bd867-7077-4358-975b-355b3b6816c2

GPS_OS_21_vs_SOC_5 Posted - 4 months ago

$SLS was going to post this article earlier... Keytruda did $25B in revenue Last Year. The GPs Keytruda Phase 2 Ovarian Cancer data, 18.4 months is better than Elahere 16.46 Months, $IMGN that got bought for $10.1B.

GPS_OS_21_vs_SOC_5 Posted - 4 months ago

@Sharkie2023 Shrinkage?? you got conned by redscam.... $imgn $10.1B Buyout - Elahere was approved for Platinum Resistant Ovarian Cancer patients based on 16.4 months of OVERAL SURVIVAL ---the same setting GPs +Keytruda Achieved an Os of 18.4 months in - once the P3 Results are announced $mrk will be buying SLS for billions - as for Gps - the Statistical Analysis Plan requires a HR for Statistical Efficacy Dr T said the Same thing Dr Jamy and Dr Levy stated, once Gps is approved for Second Remission, there will be great Benefit in earlier Settings. https://www.reddit.com/r/sellaslifesciences/comments/1c4lyuq/comment/l0405su/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button

BloodyPortfolio Posted - 4 months ago

$VKTX I want $TRIL or $IMGN kind of movement. LFG!

Market_Max Posted - 4 months ago

$TGTX The way this has moved in the last 3weeks, against the tides in the biotech market, reminds me of the price movements on $IMGN weeks before it got bought out. Fingers crossed.

GPS_OS_21_vs_SOC_5 Posted - 4 months ago

@Bob_Coyle Overlap with Gps for Ovarian Cancer . . . recall Gps + Keytruda $MRK achieved an OS of 18.4 months in a P2, with OS correlated to GPs immunotherapy, vs ELahere a FRA+ ADC, that achieved 16.46 months of OS - Same Setting $IMGN was bought for 10.1B -- and GPs + Keytruda is better.